1. Analyst View 2. Research Methodology 3. Endometrial Cancer - Epidemiology & Risk Factors 4. Endometrial Cancer Therapeutics - An Introduction 5. Market Dynamics 5.1 Drivers 5.1.1 Rising Global Endometrial Cancer Epidemics 5.1.2 Obesity Fuelling Endometrial Cancer Incidences 5.1.3 Increasing Healthcare Expenditure 5.2 Challenges 5.2.1 High Cost Associated with the Treatment 5.2.2 Increasing Stringency in Regulatory Requirements 6. Endometrial Cancer Therapeutics Market Outlook to 2023 6.1 Market Potential 7. Market Segmentation 7.1 By Therapy 7.1.1 Chemotherapy 7.1.2 Hormonal Therapy 7.1.3 Radiation Therapy 7.1.4 Surgery 7.2 By End Users 7.2.1 Research Institutes & CROs 7.2.2 Hospitals & Clinics 7.3 By Geography 7.3.1 North America 7.3.2 Europe 7.3.3 Asia Pacific 7.3.4 Rest of the World 8. Endometrial Cancer Therapeutic Drugs Pipeline Analysis 8.1 By Industry 8.1.1 By Clinical Phase 8.2 By Research Collaborations 8.2.1 By Clinical Phase 9. Trends and Developments 9.1 Womb Lining Models for further Endometriosis Investigation 9.2 Whole Exome Sequencing Aiding Identification of Targeted Therapies 9.3 Sentinel Lymph-node Mapping: Less Invasive Method for Staging 9.4 Metformin Holds Promise for Treating Endometrial Cancer 9.5 Adjuvant Chemotherapy Feasible for High Risk Endometrial Cancer 10. Strategic Mergers & Collaborations in the Endometrial Cancer Therapeutics Industry 11. Competitive Assessment 11.1 Bayer AG 11.2 F. Hoffman La Roche Ltd. 11.3 Bristol-Myers Squibb Company 11.4 Merck KGaA 11.5 Novartis AG 11.6 Takeda Pharmaceutical Company Limited 11.7 Eli Lilly and Company 11.8 Sanofi 11.9 GlaxoSmithKline plc 11.10 ArQule, Inc. List of Figures: Figure 3-1: Estimated Age-specific Incidence & Mortality Rates for Endometrial Cancer, 2016 Figure 4-1: Endometrial Cancer Therapeutic Drugs - Mechanism of Action Figure 5-1: Global Healthcare Spending (Billion US$), 2015 & 2020 Figure 5-2: Healthcare Spending by Region (Billion US$), 2015 & 2020 Figure 6-1: Global - Endometrial Cancer Therapeutics Market (Billion US$), 2016-2023 Figure 7-1: Global - Endometrial Cancer Therapeutics Market by Therapy (%), 2016 Figure 7-2: Global - Endometrial Cancer Chemotherapy Market (Billion US$), 2016 & 2023 Figure 7-3: Global - Endometrial Cancer Hormone Therapy Market (Billion US$), 2016 & 2023 Figure 7-4: Global - Endometrial Cancer Radiation Therapy Market (Billion US$), 2016 & 2023 Figure 7-5: Global - Endometrial Cancer Surgery Market (Billion US$), 2016 & 2023 Figure 7-6: Global - Endometrial Cancer Therapeutics Market by End Users (%), 2016 Figure 7-7: Global - Endometrial Cancer Therapeutics Market by Research Institutes (Billion US$), 2016 & 2023 Figure 7-8: Global - Endometrial Cancer Therapeutics Market by Hospitals (Billion US$), 2016 & 2023 Figure 7-9: Global - Endometrial Cancer Therapeutics Market by Geography (%), 2016 Figure 7-10: North America - Endometrial Cancer Therapeutics Market (Billion US$), 2016 & 2023 Figure 7-11: Europe - Endometrial Cancer Therapeutics Market (Billion US$), 2016 & 2023 Figure 7-12: Asia Pacific - Endometrial Cancer Therapeutics Market (Billion US$), 2016 & 2023 Figure 7-13: RoW - Endometrial Cancer Therapeutics Market (Billion US$), 2016 & 2023 Figure 8-1: Industrial Endometrial Cancer Therapeutic Drugs Pipeline by Clinical Phase (%), 2016 Figure 8-2: Research Pipeline Endometrial Cancer Therapeutic Drugs by Clinical Phase (%), 2016 Figure 11-1: Bayer AG - Net Sales Breakup by Business Segments (%), 2016 Figure 11-2: Bayer AG - Net Sales Breakup by Geography (%), 2016 Figure 11-3: F. Hoffman La Roche Ltd. - Revenue Breakup by Business Segments (%), 2016 Figure 11-4: Bristol-Myers Squibb Company - Revenue Breakup by Business Segments (%), 2016 Figure 11-5: Bristol-Myers Squibb Company - Revenue Breakup by Geography (%), 2016 Figure 11-6: Merck KGaA - Net Sales Breakup by Business Segments (%), 2016 Figure 11-7: Merck KGaA - Net Sales Breakup by Geography (%), 2016 Figure 11-8: Novartis AG - Net Sales Breakup by Business Segments (%), 2016 Figure 11-9: Novartis AG - Net Sales Breakup by Geography (%), 2016 Figure 11-10: Takeda Pharmaceutical Company Limited - Revenue Breakup by Geography (%), 2016 Figure 11-11: Eli Lilly and Company - Revenue Breakup by Products (%), 2016 Figure 11-12: Eli Lilly and Company - Revenue Breakup by Geography (%), 2016 Figure 11-13: Sanofi – Net Sales Breakup by Business Segments (%), 2016 Figure 11-14: Sanofi – Net Sales Breakup by Geography (%), 2016 Figure 11-15: GlaxoSmithKline plc - Breakup of Revenue by Business Segments (%), 2016 Figure 11-16: GlaxoSmithKline plc - Breakup of Revenue by Geography (%), 2016 List of Tables: Table 6-1: Potential Patients for Endometrial Cancer Therapeutics, 2015, 2020 & 2025 Table 8-1: Industrial Endometrial Cancer Therapeutic Drugs Pipeline Table 8-2: Research Collaborations Endometrial Cancer Therapeutic Drugs Pipeline Table 10-1: Strategic Mergers & Collaborations in Endometrial Cancer Therapeutics Industry, 2014-2016 Table 11-1: Top Companies by Endometrial Cancer Therapeutic Drugs in Pipeline (2016) Table 11-2: Bayer AG - Endometrial Cancer Therapeutic Drugs in Pipeline Table 11-3: Bayer AG - Key Financials (Million US$), 2014-2016 Table 11-4: F. Hoffman La Roche Ltd. - Endometrial Cancer Therapeutic Drugs in Pipeline Table 11-5: F. Hoffman La Roche Ltd. - Key Financials (Million US$), 2014-2016 Table 11-6: Bristol-Myers Squibb Company - Product Portfolio Table 11-7: Bristol-Myers Squibb Company - Endometrial Cancer Therapeutic Drugs in Pipeline Table 11-8: Bristol-Myers Squibb Company - Key Financials (Million US$), 2014 - 2016 Table 11-9: Merck KGaA - Endometrial Cancer Therapeutic Drugs in Pipeline Table 11-10: Merck KGaA - Key Financials (Million US$), 2014-2016 Table 11-11: Novartis AG - Endometrial Cancer Therapeutic Drugs in Pipeline Table 11-12: Novartis AG - Key Financials (Million US$), 2014-2016 Table 11-13: Takeda Pharmaceutical Company Limited - Endometrial Cancer Therapeutic Drugs in Pipeline Table 11-14: Takeda Pharmaceutical Company Limited - Key Financials (Million US$), 2014-2016 Table 11-15: Eli Lilly and Company - Endometrial Cancer Therapeutic Drugs in Pipeline Table 11-16: Eli Lilly and Company - Key Financials (Million US$), 2014-2016 Table 11-17: Sanofi - Endometrial Cancer Therapeutic Drugs in Pipeline Table 11-18: Sanofi - Key Financials (Million US$), 2014-2016 Table 11-19: GlaxoSmithKline plc - Endometrial Cancer Therapeutic Drugs in Pipeline Table 11-20: GlaxoSmithKline plc - Key Financials (Million US$), 2014-2016 Table 11-21: ArQule, Inc. - Endometrial Cancer Therapeutic Drugs in Pipeline Table 11-22: ArQule, Inc. - Key Financials (Million US$), 2014-2016